Results 171 to 180 of about 5,710 (181)

Long-Term Evolocumab in Patients With Familial Hypercholesterolemia

Journal of the American College of Cardiology, 2020
Frederick J Raal, Raul D Santos, Handrean Soran   +2 more
exaly  

Cost-effectiveness of Evolocumab in Patients With High Cardiovascular Risk in Spain

Clinical Therapeutics, 2017
Ben van Hout, Luís Masana, Antoni Bayes-Genis   +2 more
exaly  

Therapeutic Potential and Critical Analysis of the PCSK9 Monoclonal Antibodies Evolocumab and Alirocumab

Annals of Pharmacotherapy, 2015
C Michael White
exaly  

Evaluation of Evolocumab (AMG 145), a Fully Human Anti-PCSK9 IgG2 Monoclonal Antibody, in Subjects With Hepatic Impairment

Journal of Clinical Pharmacology, 2017
Lisa Hamilton, John P Gibbs, J Greg Slatter   +2 more
exaly  

Randomized study of evolocumab in patients with type 2 diabetes and dyslipidaemia on background statin: Pre-specified analysis of the Chinese population from the BERSON clinical trial

Diabetes, Obesity and Metabolism, 2019
Zuyi Yuan
exaly  

Alirocumab/evolocumab

Reactions Weekly, 2018
  +4 more sources

Effects of Evolocumab on Cardiovascular Events

Current Cardiology Reviews, 2017
Nasser Mikhail
exaly  

Evolocumab/rosuvastatin

Reactions Weekly, 2020
openaire   +1 more source

Alirocumab/evolocumab

Reactions Weekly, 2019
openaire   +1 more source

Alirocumab/evolocumab

Reactions Weekly
openaire   +1 more source